Plain-English translation of NCT03800693 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether the speed at which (a chemotherapy drug) is infused into your vein affects how much nerve damage you experience during cancer treatment. Half of participants will receive the medication over 2 hours, and half will receive it over 6 hours on each treatment day. The main goal is to see if the faster infusion causes less nerve pain and tingling—a common and sometimes serious side effect of this chemotherapy.
can damage nerves in your hands and feet, sometimes making it hard to do daily activities. Researchers hope that changing how quickly the medication enters your bloodstream might reduce this side effect while keeping the treatment just as effective against cancer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive your chemotherapy infusion over either 2 hours or 6 hours on day 1 of each 2-week cycle. Your treatment will continue for at least 4 cycles (8 weeks), and you will visit the hospital every 2 weeks for your infusion. Between treatments, you will answer questionnaires about any nerve pain or tingling you experience. After your chemotherapy ends, you will have follow-up visits at 1, 3, 6, 12, and 18 months to monitor how you are doing.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States